Animalcare Group PLC
LSE:ANCR

Watchlist Manager
Animalcare Group PLC Logo
Animalcare Group PLC
LSE:ANCR
Watchlist
Price: 240 GBX 1.27% Market Closed
Market Cap: 165.6m GBX
Have any thoughts about
Animalcare Group PLC?
Write Note

Animalcare Group PLC
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Animalcare Group PLC
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Animalcare Group PLC
LSE:ANCR
Research & Development
-ÂŁ2.9m
CAGR 3-Years
-6%
CAGR 5-Years
4%
CAGR 10-Years
-27%
GlaxoSmithKline PLC
LSE:GSK
Research & Development
-ÂŁ6B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-6%
AstraZeneca PLC
LSE:AZN
Research & Development
-$11B
CAGR 3-Years
-31%
CAGR 5-Years
-14%
CAGR 10-Years
-9%
Verona Pharma PLC
NASDAQ:VRNA
Research & Development
-$40.8m
CAGR 3-Years
15%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Research & Development
-$146m
CAGR 3-Years
-3%
CAGR 5-Years
-3%
CAGR 10-Years
-14%
Dechra Pharmaceuticals PLC
LSE:DPH
Research & Development
-ÂŁ57.5m
CAGR 3-Years
-27%
CAGR 5-Years
-26%
CAGR 10-Years
-22%
No Stocks Found

Animalcare Group PLC
Glance View

Market Cap
165.6m GBX
Industry
Pharmaceuticals

Animalcare Group Plc engages in the development, sale, and supply of generic veterinary medicines and animal identification products. The company is headquartered in Ripon, North Yorkshire. The company went IPO on 2008-01-15. The firm is focused on developing and commercializing prescription and over-the-counter pharmaceutical products. The firm operates in three categories within the veterinary market, which includes Companion Animals, Equine and Production Animals. The company manages international supply chain, including specialist veterinary wholesalers and distributors. The firm develops, supplies and markets products and services to the veterinary profession. The company focuses on therapeutic areas, which includes pain management, dermatology and anti-infectives. The Company’s product pipeline is Daxocox, which is a differentiated COX-2 inhibitor for the treatment of chronic pain in dogs.

ANCR Intrinsic Value
337.91 GBX
Undervaluation 29%
Intrinsic Value
Price

See Also

What is Animalcare Group PLC's Research & Development?
Research & Development
-2.9m GBP

Based on the financial report for Jun 30, 2024, Animalcare Group PLC's Research & Development amounts to -2.9m GBP.

What is Animalcare Group PLC's Research & Development growth rate?
Research & Development CAGR 10Y
-27%

Over the last year, the Research & Development growth was -60%. The average annual Research & Development growth rates for Animalcare Group PLC have been -6% over the past three years , 4% over the past five years , and -27% over the past ten years .

Back to Top